Compare AbbVie Inc (ABBV) vs Impinj Inc (PI) Price & Performance
Price performance
Price movement over the last 24 hours
Key statistics
Key statistics
AbbVie Inc vs Impinj Inc — how do they compare? AbbVie Inc trades at $254.09 (market cap $449.91B), while Impinj Inc trades at $141.17 (market cap $4.20B). The key difference: AbbVie Inc is far larger — about 107.1× Impinj Inc's market cap, and AbbVie Inc pays a 2.72% dividend while Impinj Inc pays none. Which is the better fit depends on your goals.
| ABBV | PI | |
|---|---|---|
Market Cap | $449.91B | $4.20B |
Sector | Health | Technology |
52-Week High | $261.07 | $241.91 |
52-Week Low | $184.85 | $91.34 |
Enterprise Value | $513.38B | $4.34B |
Dividend Yield | 2.72% | — |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
AbbVie (ABBV) trades at $254.44, showing slight daily weakness but maintaining a bullish technical structure with strong institutional support. The company has consistently beaten earnings expectations in recent quarters, with Q1 2026 EPS of $2.65 exceeding the $2.59 estimate. Revenue growth is accelerating, reaching $61.16B in 2025, while the immunology portfolio (Skyrizi, Rinvoq) successfully offsets Humira declines. Analyst consensus remains strongly positive with 68% buy ratings and a $266.33 price target.
The outlook is constructive with robust pipeline developments and dividend growth, though elevated valuation multiples (P/E 124.83, P/B 245.29) and looming patent cliffs in the 2030s present risks. Net income margin compression from 20.38% in 2022 to 6.9% in 2025 requires monitoring, but strong cash generation ($19.03B operating cash flow) supports continued shareholder returns.
Impinj (PI) trades at $148.00, up 4.53% today, with a bullish technical outlook supported by moving averages and a consensus analyst price target of $167.50. Recent Q1 2026 earnings beat expectations, but the company shows negative net income margins and elevated valuation multiples. Key news includes upcoming Q2 2026 results and insider selling activity.
The stock offers upside potential from strong analyst buy ratings and RFID technology leadership, but risks include persistent profitability challenges, high debt-to-asset ratio (51.52% in 2025), and sensitivity to earnings misses. Investor sentiment is mixed amid growth execution concerns.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About AbbVie Inc
AbbVie is a pharmaceutical company with a strong exposure to immunology and oncology. The firm's top drug, Humira, represents close to half of the company's current profits. The company was spun off from Abbott in early 2013. The recent acquisition of Allergan adds several new drugs in aesthetics and women's health.
Read more on ABBV →About Impinj Inc
Impinj, Inc. is a leading provider of RAIN RFID (radio-frequency identification) solutions. The company's platform includes endpoints (tag chips), connectivity devices (readers and gateways), and software, enabling businesses to wirelessly identify, locate, and authenticate everyday items. Impinj's technology is crucial for applications in retail, supply chain management, healthcare, and logistics, helping businesses to automate inventory, track assets, and improve operational efficiency.
Read more on PI →
